ArriVent BioPharma shares sink after Phase 3 trial miss
ArriVent BioPharma said its Phase 3 FURVENT trial of firmonertinib missed its primary endpoint. The stock fell sharply in premarket trading and touched a 52-week low near $12.09.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.